SOURCE: Immunovative, Inc.

Immunovative, Inc.

July 30, 2012 09:29 ET

Immunovative, Inc. Announces Launch of Website and Newsletter: ImmuNews

NEW YORK, NY--(Marketwire - Jul 30, 2012) -  Immunovative, Inc. ("IMUN") (OTCBB: IMUN) announced today that the company has launched a new website that includes information on our technology, product candidates, management team, videos and links to our social media sites, including In addition, IMUN announces the launch of ImmuNews, a monthly newsletter designed to educate and inform our shareholders and friends of happenings in the rapidly developing field of cancer immunotherapy and to provide updates on our progress toward bringing our own products to market. ImmuNews will feature each month selected news stories and published research articles in the field of cancer immunotherapy and provide expert commentary and analysis about how the news or results impact upon our current and future product development efforts. The newsletter will also report on happenings at all our operational sites around the world, including Immunovative Therapies, Ltd. (Jerusalem, Israel), Immunovative Clinical Research, Inc. (Carlsbad, California USA) and Immunovative (Thailand) Co., Ltd. (Bangkok, Thailand). Subscriptions to the Newsletter are available by sending an email to: Subscribers will receive a copy of ImmuNews each month in their email inbox.

"We are committed to providing educational and industry-based content to our shareholders and friends with respect to the immunotherapy industry. The launching of this new website and newsletter are the first steps demonstrating our commitment to provide continuous news, educational materials and updates on our progress toward bringing our product candidates to market. We welcome comments from our followers for future articles or suggestions for future feature articles or guest editorials. You can send your comments and suggestions to," said Antonio Treminio, Chairman & Chief Executive Officer of Immunovative, Inc. 

About Immunovative, Inc.:

On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including. Please visit IMUN's website at

About Immunovative Therapies, Ltd.:

Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at:


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.

Contact Information

  • For more information please contact:

    Mr. Antonio Treminio
    Chairman & Chief Executive Officer
    Immunovative, Inc.
    New York: +1-212-315-9705
    Montreal: +1-514-840-3697
    Email: Email Contact

    Dr. Michael Har-Noy
    Founder & Chief Executive Officer
    Immunovative Therapies, Ltd.
    Israel Tel: +972-2-6506288
    US Tel: +1-760-444-9040
    Email: Email Contact